Home
  >  
Section 66
  >  
Chapter 65,614

The Role of the Programmed Death Receptor-1/Programmed Death Ligand-1: Immunologic Checkpoint in Human Papillomavirus-Associated Head and Neck Squamous Cell Carcinoma

Kunkle, C.; Rosado, F.G.

Archives of Pathology and Laboratory Medicine 142(6): 719-720

2018


ISSN/ISBN: 0003-9985
PMID: 29848031
DOI: 10.5858/arpa.2017-0561-ra
Accession: 065613259

Download citation:  
Text
  |  
BibTeX
  |  
RIS

- There has been increasing interest in understanding the role of programmed death receptor-1 (PD-1)/programmed death ligand-1 (PD-L1) pathway in cancer biology and its clinical significance in cancer therapy. - To discuss the studies of the PD-1/PD-L1 pathway in human papillomavirus-positive head and neck squamous cell carcinoma, focusing on the pathogenesis of cancer, characterization of the tumor microenvironment, and the effect of such studies in laboratory medicine. - Data sources included peer-reviewed literature and reputable online sources. - To date, there are few studies of PD-1 and PD-L1 in human papillomavirus-positive head and neck squamous cell carcinoma. There is evidence that the PD-1/PD-L1 pathway has a role in this type of cancer; however, further studies are needed to better characterize the effect of the human papillomavirus and its use as a marker of therapy response.

PDF emailed within 0-6 h: $19.90